Literature DB >> 28905233

Gated thoracic magnetic resonance angiography at 3T: noncontrast versus blood pool contrast.

Chengcheng Zhu1, Henrik Haraldsson2, Kimberly Kallianos2, Liang Ge3, Elaine Tseng3, Travis Henry2, David Saloner2, Michael D Hope2.   

Abstract

Both noncontrast and contrast-enhanced approaches to gated thoracic magnetic resonance angiography (MRA) for aortic root evaluation have been reported at 3T. We compare qualitative and quantitative image quality measures for the two approaches, and assess the reproducibility of standard aortic measurements. Respiratory and cardiac gated MRA of the chest was performed at 3T in 45 patients: 23 after administration of iron-based blood pool contrast, and 22 without contrast. Image quality was assessed with a 5-point Likert scale, vessel lumen-to-muscle contrast ratios, and vessel wall sharpness. Two reviewers measured the ascending aorta diameter and valve annulus area. Interrater agreement was assessed using Bland-Altman plots and coefficient of variation (CV). Qualitative image quality was better with blood pool contrast in all principal vessels of the chest (mean Likert of 4.20 ± 0.79 vs. 2.60 ± 0.77, p < 0.001). Quantitative assessment was also improved with higher contrast ratios in all vessels (5.26 ± 3.3 vs. 1.90 ± 0.53, p < 0.001), and greater sharpness of the aortic annulus and ascending aorta (0.70 ± 0.16 vs. 0.56 ± 0.14 mm-1, p < 0.001, and 0.87 ± 0.16 vs. 0.62 ± 0.16 mm-1, p = 0.008, respectively). Reproducibility of measurement was marginally better for the ascending aorta diameter (CV of 2.80 vs. 3.23%), but substantially increased for the aortic valve annulus area with blood pool contrast (CV of 4.93 vs. 7.32%). The use of a blood pool contrast agent for gated thoracic MRA improves image quality compared to a noncontrast technique, and provides more reproducible measurements of the aortic valve annulus area.

Entities:  

Keywords:  Aorta; Contrast; MRA; Measurement reproducibility; TAVR

Mesh:

Substances:

Year:  2017        PMID: 28905233      PMCID: PMC5826886          DOI: 10.1007/s10554-017-1242-8

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  16 in total

1.  Multimodality imaging in transcatheter aortic valve implantation and post-procedural aortic regurgitation: comparison among cardiovascular magnetic resonance, cardiac computed tomography, and echocardiography.

Authors:  Andrew Jabbour; Tevfik F Ismail; Neil Moat; Ankur Gulati; Isabelle Roussin; Francisco Alpendurada; Bradley Park; Francois Okoroafor; Anita Asgar; Sarah Barker; Simon Davies; Sanjay K Prasad; Michael Rubens; Raad H Mohiaddin
Journal:  J Am Coll Cardiol       Date:  2011-11-15       Impact factor: 24.094

2.  A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI.

Authors:  Martin R Prince; Hong Lei Zhang; Shalini G Chabra; Paula Jacobs; Yi Wang
Journal:  J Xray Sci Technol       Date:  2003-01-01       Impact factor: 1.535

3.  Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation.

Authors:  Jan-Malte Sinning; Alexander Ghanem; Hannah Steinhäuser; Viktoria Adenauer; Christoph Hammerstingl; Georg Nickenig; Nikos Werner
Journal:  JACC Cardiovasc Interv       Date:  2010-11       Impact factor: 11.195

4.  Two-year outcomes after transcatheter or surgical aortic-valve replacement.

Authors:  Susheel K Kodali; Mathew R Williams; Craig R Smith; Lars G Svensson; John G Webb; Raj R Makkar; Gregory P Fontana; Todd M Dewey; Vinod H Thourani; Augusto D Pichard; Michael Fischbein; Wilson Y Szeto; Scott Lim; Kevin L Greason; Paul S Teirstein; S Chris Malaisrie; Pamela S Douglas; Rebecca T Hahn; Brian Whisenant; Alan Zajarias; Duolao Wang; Jodi J Akin; William N Anderson; Martin B Leon
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

5.  Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature.

Authors:  Ganesh Athappan; Eshan Patvardhan; E Murat Tuzcu; Lars Georg Svensson; Pedro A Lemos; Chiara Fraccaro; Giuseppe Tarantini; Jan-Malte Sinning; Georg Nickenig; Davide Capodanno; Corrado Tamburino; Azeem Latib; Antonio Colombo; Samir R Kapadia
Journal:  J Am Coll Cardiol       Date:  2013-04-16       Impact factor: 24.094

6.  Vascular Imaging With Ferumoxytol as a Contrast Agent.

Authors:  Michael D Hope; Thomas A Hope; Chengcheng Zhu; Farshid Faraji; Henrik Haraldsson; Karen G Ordovas; David Saloner
Journal:  AJR Am J Roentgenol       Date:  2015-06-23       Impact factor: 3.959

7.  Ferumoxytol MRA for transcatheter aortic valve replacement planning with renal insufficiency.

Authors:  Kimberly Kallianos; Travis S Henry; Yerem Yeghiazarians; Jeffrey Zimmet; Kendrick A Shunk; Elaine E Tseng; Vaikom Mahadevan; Michael D Hope
Journal:  Int J Cardiol       Date:  2016-12-30       Impact factor: 4.164

Review 8.  Safety and technique of ferumoxytol administration for MRI.

Authors:  Shreyas S Vasanawala; Kim-Lien Nguyen; Michael D Hope; Mellena D Bridges; Thomas A Hope; Scott B Reeder; Mustafa R Bashir
Journal:  Magn Reson Med       Date:  2016-02-18       Impact factor: 4.668

9.  Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement.

Authors:  Vinod H Thourani; W Brent Keeling; Eric L Sarin; Robert A Guyton; Patrick D Kilgo; Ameesh B Dara; John D Puskas; Edward P Chen; William A Cooper; J David Vega; Cullen D Morris; Michael E Halkos; Omar M Lattouf
Journal:  Ann Thorac Surg       Date:  2011-05-04       Impact factor: 4.330

10.  Cardiovascular magnetic resonance for the assessment of patients undergoing transcatheter aortic valve implantation: a pilot study.

Authors:  Alessio La Manna; Alessandra Sanfilippo; Davide Capodanno; Antonella Salemi; Gesualdo Polizzi; Wanda Deste; Glauco Cincotta; Alessandra Cadoni; Anna Marchese; Michele Figuera; Gian P Ussia; Rosetta Pittalà; Carmelo Privitera; Corrado Tamburino
Journal:  J Cardiovasc Magn Reson       Date:  2011-12-27       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.